• FDA's Fast Track designation speeds up the development of new biologic drugs for rare diseases

YONGIN, South Korea, June 10, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA (Sanfilippo syndrome Type A) treatment, GC1130A.

This...